Search
Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen
go.drugbank.com/drugs/DB18661ApprovedThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.
Influenza A virus A/Sydney/1304/2022 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB19321ApprovedThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.
Influenza A virus A/Massachusetts/18/2022 (H3N2) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB19322ApprovedWithdrawnThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.
Influenza A virus A/Thailand/8/2022 IVR-237 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB19323ApprovedWithdrawnThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.
Influenza A virus A/Thailand/8/2022 IVR-237 antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB19324ApprovedWithdrawnThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.
Influenza A Virus A/Thailand/8/2022 IVR-237 (H3N2) whole
go.drugbank.com/drugs/DB19413ApprovedThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.
Influenza A virus A/Darwin/6/2021 (H3N2) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB16922ApprovedThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.
Influenza B virus B/Austria/1359417/2021 BVR-26 antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB16925ApprovedWithdrawnThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.
Chlorpropamide
go.drugbank.com/drugs/DB00672ApprovedWithdrawnIt belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. … Up to 80% of the single oral dose of chlorpropramide is metabolized, likely in the liver; 80-90% of the dose is excreted in urine as unchanged drug and metabolites.
Lubiprostone
go.drugbank.com/drugs/DB01046ApprovedInvestigationalA prostaglandin E1 derivative, lubiprostone is a bicyclic fatty acid that activates ClC-2 chloride channels located on the apical side of the gastrointestinal epithelial cells. … Activation of these channels promotes the secretion of a chloride-rich fluid that soften the stool, increase gastrointestinal motility, and induce spontaneous bowel movements (SBM).
Categories: Prostaglandins E